Physician profile
Daniel J Lynch
NPI 1477548782
$26,665.80
in general payments reported to CMS, 2019-2025
65 companies · $3,726 in 2025
The $3,726 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,750 · 2020: $3,331 · 2021: $4,433 · 2022: $3,375 · 2023: $2,930 · 2024: $4,121 · 2025: $3,726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,776.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $4,632.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $3,610.57 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $1,929.82 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $1,849.49 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,774.07 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,616.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,521.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,011.73 | 2019-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Sanofi-Aventis U.S. LLC | $955.85 | 2019-2024 | |
| Allergan, INC. | $666.44 | 2019-2020 | |
| Glaxosmithkline, LLC. | $584.84 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $575.42 | 2019-2025 | Glassia |
| Corcept Therapeutics | $510.35 | 2025 | Korlym |
| Amarin Pharma, INC. | $478.65 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $429.65 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.